Completed PHASE2 INTERVENTIONAL 2-arm NCT00448292

A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of PRX-00023 in Patients With Major Depressive Disorder.

Sponsor: Epix Pharmaceuticals, Inc.

Conditions Major Depressive Disorder (MDD)

Interventions PRX-00023 Placebo for PRX-00023

Updated 6 times since 2017 Last updated: Nov 9, 2007 Started: Mar 31, 2007 Completion: Nov 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00448292, this PHASE2 trial focuses on Major Depressive Disorder (MDD) and remains completed. Sponsored by Epix Pharmaceuticals, Inc., it has been updated 6 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Epix Pharmaceuticals, Inc.

Data source: Epix Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Bellevue, United States , Charleston, United States , Charlotte, United States , Chicago, United States , Dallas, United States , Encino, United States , Jacksonville, United States , Lake Jackson, United States , Los Alamitos, United States and 11 more locations